A further question was addressed in this study: since the presence of AMPK-α1 in the tumour progenitor cells provided protection against T-ALL, would additional protection be provided by treatment with pharmacological activators of AMPK? Here, PRKAA2 is linked to acute lymphoblastic leukemia.